ONCOLOGY Diagnostics

THE NEED FOR A RAPID TREATMENT INITIATION RESPONSE TOWARDS PATIENTS

Fast initiation of immunotherapy or targeted therapy as first-line treatment is crucial for cancer patients, as it increases overall survival rates. Timely detection of biomarkers therefore is very important. Today, turnaround times of reference technologies are on average 18 days, with 14% of patients waiting longer than a month to be able to start treatment. Ninety-five percent of the patients have to wait more than a week in order to receive the biomarker results. This means that precious time is lost whereas treatment initiation could have been started and unnecessary use of chemotherapy with its side effects could have been avoided.

IDYLLA, THE NEXT LEVEL IN DISEASE INTERCEPTION 

Idylla, a fully automated, sample-to-result PCR based molecular diagnostics system, provides same-day results enabling physicians to make timely decisions on patients’ therapy. Idylla can be used with multiple sample types, including solid and liquid biopsies. This flexibility allows use of the system for diagnostic, research, and potentially future monitoring applications. Idylla, with its compact scalable design and outstanding ease-of-use, overcomesthe traditional barriers of molecular diagnostics, allowing it to be used in virtually any laboratory setting  

 
Fast diagnostics, allow faster initiation of targeted therapy for cancer patients. Idylla, Biocartis’ fully automated molecular diagnostics system, is the first and only molecular diagnostic system that combines unsurpassed ease-of-use, speed and accuracy on multiple sample types. With its compact, scalable design and outstanding ease-of-use, Idylla overcomes the traditional barriers of molecular diagnostics, allowing it to be used in virtually any laboratory setting. And by providing same-day-results, Idylla enables physicians to make timely decisions on patients’ therapy.

more details ... 

LOAA ANALYZER  - DIGITAL PCR 

CML is a malignancy of the myeloid cell lineage characterized by a recurrent chromosomal abnormality: the Philadelphia chromosome, which results from the reciprocal translocation of the chromosomes 9 and 22. The Philadelphia chromosome contains a fusion gene called BCR-ABL1. The BCR-ABL1 codes for an aberrantly functioning tyrosine kinase that drives the malignant proliferation of the founding clone. The Dr. PCR™ BCR-ABL1 Major IS Detection Kit is a molecular in vitro diagnostic test that detects BCR-ABL1 fusion gene in leukemias including CML. The kit uses nucleic acid amplification based on a dual labeled hydrolysis probe, TaqMan and target specific primers. 

"Digital RT-PCR on SEMICONDUCTOR 20K wells chip Silicon MEMS* and microfluidics technology. These are nano wells in which real time PCR takes place. PCR mixture is spreaded in 20K  wells. The semiconductor at the bottom controls the process. Even in only one well amplifies, the signal is detected. Because of this, Dr. PCR has high sensitivity especially in low concentration samples."

more details ... 

OSNA - SENTINEL LYMPH NODE ANALYSIS 

Axillary management and the relevance of sentinel lymph node biopsy (SLNB) have undergone major changes in the last years. Clinical trials, which have investigated less invasive treatment approaches as a replacement of axillary surgery, indicate that axillary dissection can be omitted in patients with limited metastatic involvement. Consequently, treatment decisions and nodal staging more often have to be based solely on the diagnostic information derived from the sentinel lymph node (SLN).

More than 100 publications provide evidence on the clinical utility of using OSNA and the CK19 copy number for SLN assessment. They show that CK19 provides predictive and prognostic information beyond conventional pathology assessment. This helps clinicians better select who can be safely spared an ALND, allows more personalised treatment decisions and improves patients’ quality of life.

more details ... 